



NVTH Course Bleeding Disorders–3-5 April 2017
Golden Tulip Hotel Westduin–Koudekerke, Zeeland

Monday April 3

12.00 – 13.00	Registration and lunch
13.00 – 13.05	<i>Introduction</i> Shirley Uitte de Willige
13.05 – 13.30 (B)	<i>Primary hemostasis - overview</i> Shirley Uitte de Willige
13.30 – 14.15 (B)	<i>Secondary hemostasis - overview</i> Henri Versteeg
14.15 – 15.00 (C)	<i>Haemophilia</i> Karin Fijnvandraat
15.00 – 15.30	Coffee break
15.30 – 16.00 (B)	<i>Immunogenicity of factor VIII</i> Jan Voorberg
16.00 – 16.30 (C)	<i>(Clinical) determinants of inhibitor development</i> Samantha Gouw
16.30 – 17.00 (B)	<i>Coagulation defects in liver disease</i> Ton Lisman
17.00 – 17.30 (C)	<i>Major bleeding in trauma and surgery</i> Marieke Kruip
17.30 – 19.30	Dinner
19.30 – 21.00 (B/C)	<i>Next Generation Researchers – Laptop session</i> PhD students introduce themselves and their project in 3 slides on a laptop in small groups



NVTH Course Bleeding Disorders–3-5 April 2017
Golden Tulip Hotel Westduin–Koudekerke, Zeeland

Tuesday April 4

08.30 – 09.30 (B/C)	<i>Principles of hemostasis diagnostics</i> Joost Meijers
09.30 – 10.00 (B)	<i>Platelet signalling</i> Rory Koenen
10.00 – 10.30 (C)	<i>(Congenital) platelet defects</i> Roger Schutgens
10.30 – 11.00	Coffee break
11.00 – 11.40 (B)	<i>Biosynthesis and function of von Willebrand factor</i> Ruben Bierings
11.40 – 12.20 (B/C)	<i>Von Willebrand disease – diagnosis and genetics</i> Jeroen Eikenboom
12.20 – 13.00 (C)	<i>Von Willebrand disease – symptoms and treatment</i> Frank Leebeek
13.00 – 14.00	Lunch
14.00 – 15.30	<i>Case problems in hemostasis - assignment</i> Preparation by students
15.30 – 17.00	<i>Case problems in hemostasis - discussion</i> Joost Meijers, Jeroen Eikenboom, Shirley Uitte de Willige
17.00 -	Cooking workshop and dinner



NVTH Course Bleeding Disorders–3-5 April 2017
Golden Tulip Hotel Westduin–Koudekerke, Zeeland

Wednesday April 5

08.30 – 09.30

Preparation pro/con Debate

Papers

- A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A. Peyvande et al. N Engl J Med 2016;374:2054-64
- Factor VIII Products and Inhibitor Development in Severe Hemophilia A. Gouw et al. N Engl J Med 2013;368:231-9
- Engineering less immunogenic and antigenic FVIII proteins. Pratt. Cellular Immunology 301 (2016) 12–7

09.30 – 10.00

Debate:

Hemophilia A patients should be treated with plasma-derived factor VIII concentrates to minimize inhibitor development

Moderator Roger Schutgens

10.00 – 10.30

Coffee break

10.30 – 11.30

The patient's perspective

Minette van der Ven

Fred Cuijpers

11.30 – 12.30

Lunch